Viatris' net sales 2021-2023 by market
In 2023, Viatris reported net sales of 9.25 billion U.S. dollars in developed markets compared to 9.77 billion U.S dollars in 2022. This statistic shows the net sales of pharmaceutical company Viatris from 2021 to 2023, distributed by its four regional markets.
Viatris is a global healthcare company headquartered in the United States with global centers in Pennsylvania, Shanghai and Hyderabad, India. The company was formed in November 2020 through the combination of Mylan and the Upjohn Business (owned by Pfizer Inc.). Its global portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized iconic brands (such as Viagra, Xanax, Lipitor).
Viatris is a global healthcare company headquartered in the United States with global centers in Pennsylvania, Shanghai and Hyderabad, India. The company was formed in November 2020 through the combination of Mylan and the Upjohn Business (owned by Pfizer Inc.). Its global portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized iconic brands (such as Viagra, Xanax, Lipitor).
